Research programme: neurodegenerative disorders therapeutics - Samaritan/McGill University

Drug Profile

Research programme: neurodegenerative disorders therapeutics - Samaritan/McGill University

Alternative Names: Caprospinol; SP-004; SP-008; SP-04; SP-04m; SP-08; SP-233

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Georgetown University; McGill University; Samaritan Pharmaceuticals
  • Developer CHDI; McGill University; Samaritan Pharmaceuticals
  • Class Caproates; Piperazines; Small molecules; Spirostans; Steroids
  • Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Sigma-1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Huntington's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Huntington's-disease in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada (PO)
  • 24 Jan 2008 Preclinical trials in Huntington's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top